Lo Tzu-Chen, Chen Yu-Yen, Hung Man-Chen, Chou Pesus
Department of Medical Education, Taichung Veterans General Hospital, Taichung 407, Taiwan.
Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 112, Taiwan.
J Clin Med. 2022 Jul 26;11(15):4325. doi: 10.3390/jcm11154325.
Latanoprostene bunod (LBN) 0.024%, a newly approved glaucoma eye drop, is metabolized into latanoprost acid and a nitric oxide (NO)-donating moiety, thus increasing the outflow of aqueous humor through the uveoscleral and trabecular routes, respectively. This study aimed to evaluate the intraocular pressure (IOP)-lowering effect of LBN among patients with open-angle glaucoma (OAG) and ocular hypertension (OHT). The effectiveness of LBN was also compared with timolol maleate 0.5% and latanoprost 0.005%. We searched PubMed and Embase between 1 January 2010, and 31 March 2022 and adopted only peer-reviewed clinical studies in our meta-analysis. A total of nine studies (2389 patients with OAG or OHT) assessing the IOP-reduction effect of LBN were included. Standardized mean differences (SMDs) of IOP between post-treatment time points (2 weeks, 6 weeks, 3 months, 6 months, 9 months, and 12 months) and baseline were calculated. The pooled analysis according to each time point revealed a significant IOP drop after LBN treatment (all p values for SMD < 0.05). In addition, LBN revealed a significantly stronger efficacy in decreasing IOP than timolol maleate 0.5% and latanoprost 0.005% during the follow-up period of three months. No serious side effects of LBN 0.024% were reported. Our study concluded that LBN could achieve good performance for IOP reduction in patients with OAG and OHT. The safety was favorable with no severe side effects.
0.024%的比马前列素丁酯（LBN）是一种新获批的用于治疗青光眼的眼药水，它可代谢为拉坦前列酸和一个释放一氧化氮（NO）的部分，从而分别通过葡萄膜巩膜途径和小梁途径增加房水流出。本研究旨在评估LBN在开角型青光眼（OAG）和高眼压症（OHT）患者中的降眼压效果。还将LBN的有效性与0.5%的马来酸噻吗洛尔和0.005%的拉坦前列素进行了比较。我们检索了2010年1月1日至2022年3月31日期间的PubMed和Embase数据库，并且在我们的荟萃分析中仅采用了经同行评审的临床研究。总共纳入了9项评估LBN降眼压效果的研究（2389例OAG或OHT患者）。计算了治疗后各时间点（2周、6周、3个月、6个月、9个月和12个月）与基线之间眼压的标准化平均差（SMD）。根据每个时间点进行的汇总分析显示，LBN治疗后眼压显著下降（所有SMD的p值均<0.05）。此外，在三个月的随访期内，LBN在降低眼压方面显示出比0.5%的马来酸噻吗洛尔和0.005%的拉坦前列素更强的疗效。未报告0.024%的LBN有严重副作用。我们的研究得出结论，LBN在降低OAG和OHT患者的眼压方面表现良好。安全性良好，无严重副作用。
